Q1 2025 Swedish Orphan Biovitrum AB (publ) Earnings Call Transcript
Key Points
- Swedish Orphan Biovitrum AB (BIOVF) reported a strong first quarter with a 23% growth in their strategic portfolio, excluding seasonal RSV products and discontinued ReFacto manufacturing revenues.
- The company achieved a significant market share of 57% for Altuvoct in Germany within nine months of its launch.
- The haematology segment showed robust growth, driven by products like Doptelet, Aspaveli, and the launch of Altuvoct.
- Swedish Orphan Biovitrum AB (BIOVF) received FDA priority review for Gamifant in the US, with a PDUFA date set for late June.
- The company is actively expanding its pipeline with promising developments in areas such as nephrology and chronic refractory gout.
- Vonjo sales were negatively impacted by stocking issues and gross-to-net adjustments, leading to a 6% decline in revenues.
- Immunology revenues declined by 21% due to the expected decline of Synagis and seasonal shifts in Beyfortus royalties.
- The company faces competition for Aspaveli from new oral medicines, which could impact its market performance.
- There is uncertainty regarding the launch of Altuvoct in France and the UK, with ongoing discussions needed for market entry.
- Potential tariffs on pharmaceutical products could impact the company's operations, though the exact effects remain speculative.
()- -
Hello, everyone. This is Guido Oelkers, CEO of Sobi. We are delighted to welcome you to the first quarter video conference of 2025 call for investors and analysts. We posted this presentation to sobi.com earlier today.
And straight to the forward-looking statement, we would like to remind you of the usual provisions on the statement about expectations, projections, or future events. Unlike stated otherwise, we will be making comments that mostly relate to the first quarter at constant exchange rate in million Swedish krona.
Let's move to the agenda. And today, we plan to cover the following key aspects of the Q1 report. I'm joined by Henrik Stenqvist, our CFO; and Lydia Abad-Franch, Head of R&D and Chief Medical Officer. We plan to review the presentation first and then have Q&A until around 4:30 Swedish time. (Event Instructions)
Let's go to slide number 4. I mean we -- as you have seen, this has been a pretty strong quarter with solid
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
